IonicRF™: a novel step in technology for radiofrequency ablation treatments

2022 ◽  
Author(s):  
Harjot S Bhandal ◽  
Chau Vu ◽  
Jason E Pope
Keyword(s):  
Chronic Pain ◽  
Radiofrequency Ablation ◽  
Sacroiliac Joint ◽  
Procedure Time ◽  
Wide Range ◽  
Chronic Pain Conditions ◽  
Lumbar Facet

Radiofrequency ablation (RFA) has been utilized since the 1970s to treat various painful conditions. The technology has evolved from its initial use to treat lumbar facet mediated pain with monopolar lesioning to now treat a plethora of chronic pain conditions. This article reviews Abbott Corporation's (IL, USA) IonicRF™ generator. The IonicRF generator utilizes an intelligent power algorithm that improves efficiency and reduces procedure time. The generator also carries a wide range of RFA therapies such as monopolar, bipolar, pulsed or pulsed dose radiofrequency. Additionally, the IonicRF RFA generator is compatible with the Simplicity™ RF probe (Abbott) which allows for efficient and effective denervation of the sacroiliac joint.

Interpreting the MINT Randomized Trials Evaluating Radiofrequency Ablation for Lumbar Facet and Sacroiliac Joint Pain

2018 ◽  
Vol 43 (1) ◽  
pp. 68-71 ◽  
Author(s):  
David A. Provenzano ◽  
Asokumar Buvanendran ◽  
Oscar A. de León-Casasola ◽  
Samer Narouze ◽  
Steven P. Cohen
Keyword(s):  
Radiofrequency Ablation ◽  
Sacroiliac Joint ◽  
Joint Pain ◽  
Randomized Trials ◽  
Sacroiliac Joint Pain ◽  
Lumbar Facet

scholarly journals Long-Term Safety and Efficacy of Sub-Lingual Ketamine Trouches / Lozenges in Chronic Non-Malignant Pain Management

2020 ◽  
Author(s):  
Ben Nelson Maudlin ◽  
Stephen Bruce Gibson ◽  
Arun Aggarwal
Keyword(s):  
Chronic Pain ◽  
Pain Management ◽  
Side Effects ◽  
Case Series ◽  
Analgesic Agent ◽  
Duration Of Treatment ◽  
Retrospective Case ◽  
Wide Range ◽  
Chronic Pain Conditions

Chronic non-malignant pain is a disabling condition that results in a reduction in function and quality of life when inadequately managed. Sub-lingual ketamine has been shown to be efficacious for use in chronic pain. Despite its use for decades in chronic non-malignant pain, there is no published long-term data on safety, side effects or adverse drug reactions. We present a retrospective review of twenty-nine patients (n=29) from a metropolitan tertiary pain service who have been receiving sub-lingual ketamine trouches / lozenges between the period of 2012-2019. There was a wide range of dosages used from 25-600mg in divided doses. The duration of treatment ranged from 2-89 months. There was no association with either the dosage or duration of treatment and frequency of side effects. There was an overall reduction in the use of opioids, gabapentinoids or benzodiazepines in 59% of patients with 39% having a complete cessation of an analgesic agent. Side effects were reported in 24%, but only 7% discontinued the treatment due to the side effect (drowsiness). There were no reports of renal impairment, cystitis or hepatotoxicity. This retrospective case-series has demonstrated that sub-lingual ketamine is a safe and effective analgesic agent to use in chronic non-malignant pain management. It is indicated in a variety of chronic pain conditions and has an excellent safety profile, with no association between the frequency in side effects and duration of therapy or total daily dosages. The study has also shown that the safe dose may be higher than the previous consensus.

Retrospective analysis on the effect of spinal cord stimulation on opioid consumption

2020 ◽  
Author(s):  
Awinita Barpujari ◽  
Michael A Erdek
Keyword(s):  
Spinal Cord ◽  
Chronic Pain ◽  
Retrospective Analysis ◽  
Spinal Cord Stimulation ◽  
Alternative Therapy ◽  
Opioid Consumption ◽  
Opioid Use ◽  
Number Of Patients ◽  
Chronic Pain Conditions ◽  
Post Trial

Aim: Spinal cord stimulation (SCS) is used to clinically manage and/or treat several chronic pain etiologies. A limited amount is known about the influence on patients' use of opioid pain medication. This retrospective analysis evaluated SCS effect on opioid consumption in patients presenting with chronic pain conditions. Materials & methods: Sixty-seven patients underwent a temporary trial device, permanent implant or both. Patients were divided for assessment based on the nature of their procedure(s). Primary outcome was change in morphine equivalent dose (MED), ascertained from preoperative and postoperative medication reports. Results: Postoperative MED was significantly lower in patients who received some form of neuromodulation therapy. Pretrial patients reported an average MED of 41.01 ± 10.23 mg per day while post-trial patients reported an average of 13.30 ± 5.34 mg per day (p < 0.001). Pre-implant patients reported an average MED of 39.14 ± 13.52 mg per day while post-implant patients reported an average MED of 20.23 ± 9.01 mg per day (p < 0.001). There were no significant differences between pre-trial and pre-implant MED, nor between post-trial and post-implant MED. Of the 42 study subjects who reported some amount of pre-intervention opioid use, 78.57% indicated a lower MED (n = 33; p < 0.001), 16.67% indicated no change (n = 7) and 4.76% (n = 2) indicated a higher MED, following intervention. Moreover, SCS therapy resulted in a 26.83% reduction (p < 0.001) in the number of patients with MED >50 mg per day. Conclusion: Spinal cord stimulation may reduce opioid use when implemented appropriately. Neuromodulation may represent alternative therapy for alleviating chronic pain which may avoid a number of deleterious side effects commonly associated with opioid consumption.

scholarly journals Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine

2021 ◽  
Vol 3 (5) ◽  
pp. e383-e392
Author(s):  
Jo Nijs ◽  
Steven Z George ◽  
Daniel J Clauw ◽  
César Fernández-de-las-Peñas ◽  
Eva Kosek ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Precision Medicine ◽  
Central Sensitisation ◽  
Chronic Pain Conditions

Interdisciplinary Teams in Endometriosis Care

2020 ◽  
Vol 38 (02/03) ◽  
pp. 227-234
Author(s):  
Catherine Allaire ◽  
Alicia Jean Long ◽  
Mohamed A. Bedaiwy ◽  
Paul J. Yong
Keyword(s):  
Chronic Pain ◽  
Interdisciplinary Team ◽  
Multidisciplinary Care ◽  
Complex Problem ◽  
Interdisciplinary Teams ◽  
Team Approach ◽  
Team Care ◽  
Psychological Therapies ◽  
Published Evidence ◽  
Chronic Pain Conditions

AbstractEndometriosis-associated chronic pelvic pain can at times be a complex problem that is resistant to standard medical and surgical therapies. Multiple comorbidities and central sensitization may be at play and must be recognized with the help of a thorough history and physical examination. If a complex pain problem is identified, most endometriosis expert reviews and guidelines recommend multidisciplinary care. However, there are no specific recommendations about what should be the components of this approach and how that type of team care should be delivered. There is evidence showing the effectiveness of specific interventions such as pain education, physical therapy, psychological therapies, and pharmacotherapies for the treatment of chronic pain. Interdisciplinary team models have been well studied and validated in other chronic pain conditions such as low back pain. The published evidence in support of interdisciplinary teams for endometriosis-associated chronic pain is more limited but appears promising. Based on the available evidence, a model for an interdisciplinary team approach for endometriosis care is outlined.

EAN guidelines on central neurostimulation therapy in chronic pain conditions

2016 ◽  
Vol 23 (10) ◽  
pp. 1489-1499 ◽  
Author(s):  
G. Cruccu ◽  
L. Garcia-Larrea ◽  
P. Hansson ◽  
M. Keindl ◽  
J.-P. Lefaucheur ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Chronic Pain Conditions

473: Subcutaneous Targeted Stimulation in Chronic Pain Conditions - a 6 Year Retrospective Study

2008 ◽  
Vol 33 (5) ◽  
pp. e200-e200 ◽  
Author(s):  
T GOROSZENIUK ◽  
R REDDY ◽  
S KOTHARI ◽  
R KHAN ◽  
N PRATAP ◽  
...  
Keyword(s):  
Chronic Pain ◽  
Retrospective Study ◽  
Chronic Pain Conditions

Ketamine Infusions for Complex Regional Pain Syndrome

2016 ◽  
Author(s):  
Roy K. Esaki
Keyword(s):  
Chronic Pain ◽  
Complex Regional Pain Syndrome ◽  
Hepatic Dysfunction ◽  
Case Reports ◽  
Pain Syndrome ◽  
Nmda Receptor Antagonist ◽  
Treatment Resistant ◽  
Urinary Tract Symptoms ◽  
Chronic Pain Conditions ◽  
Lower Urinary

Ketamine is an N-methyl-d-aspartate (NMDA) receptor antagonist that has been increasingly used in the management of treatment-resistant chronic pain conditions, particularly representing neuropathic involvement or central sensitization. Complex regional pain syndrome (CRPS) is a prototypical condition often treated with ketamine infusions. Although the analgesic benefits of ketamine as an opioid-sparing adjunct in the preoperative period have been well studied, the use of ketamine to mitigate chronic pain conditions remains largely anecdotal, composed largely of case reports and uncontrolled small studies. The limited evidence and published reports support the use of ketamine infusions as one aspect of a comprehensive, multimodal approach for CRPS. Although ketamine infusions are relatively safe when titrated appropriately, with minimal respiratory depression, side effects include sympathetic activation, unpleasant psychomimetic effects, lower urinary tract symptoms, and hepatic dysfunction. 

Sign in / Sign up

Export Citation Format

Share Document